Article
Biochemistry & Molecular Biology
Nabil F. Saba, Conor E. Steuer, Asari Ekpenyong, Ashley McCook-Veal, Kelly Magliocca, Mihir Patel, Nicole C. Schmitt, William Stokes, James E. Bates, Soumon Rudra, Jill Remick, Mark McDonald, Marin Abousaud, Aik Choon Tan, Muhammad Zaki Hidayatullah Fadlullah, Ritu Chaudhary, Jameel Muzaffar, Kedar Kirtane, Yuan Liu, Georgia Z. Chen, Dong M. Shin, Yong Teng, Christine H. Chung
Summary: PD-1 therapy is standard treatment for recurrent metastatic head and neck squamous cell carcinoma. The combination of Pembrolizumab and Cabozantinib shows promising clinical activity. Further research is needed.
Article
Oncology
Julie E. Bauman, Nabil F. Saba, Denise Roe, Jessica R. Bauman, John Kaczmar, Aarti Bhatia, Jameel Muzaffar, Ricklie Julian, Steven Wang, Shethal Bearelly, Audrey Baker, Conor Steuer, Anshu Giri, Barbara Burtness, Sara Centuori, Carlos Caulin, Robert Klein, Kathylynn Saboda, Stefanie Obara, Christine H. Chung
Summary: This study evaluated the efficacy of combining ficlatuzumab and cetuximab in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The results showed that the combination therapy had a significant improvement in progression-free survival compared to monotherapy, and cMet overexpression associated with HPV-negative disease was associated with reduced risk of progression.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Medicine, General & Internal
Mayur D. Mody, James W. Rocco, Sue S. Yom, Robert Haddad, Nabil F. Saba
Summary: Head and neck cancer is the seventh most common type of cancer worldwide, with the predominant risk factors being tobacco use, alcohol abuse, and oncogenic viruses. Treatment typically involves a multidisciplinary approach with surgery, radiotherapy, and systemic therapy, and is challenging due to site-specific and histology-specific variations.
Article
Biochemistry & Molecular Biology
Xun Yuan, Ming Yi, Wei Zhang, Linping Xu, Qian Chu, Suxia Luo, Kongming Wu
Summary: The development of immune checkpoint inhibitors has revolutionized treatment for head and neck cancer, but patients often exhibit primary resistance to immunotherapy. Ongoing trials are exploring combinations of immunotherapy with other interventions to improve treatment outcomes. As novel strategies are leveraged, the significance of immunotherapy in recurrent/metastatic head and neck cancer is being further revealed.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
(2021)
Article
Oncology
Kirsty Taylor, Jinfeng Zou, Marcos Magalhaes, Marc Oliva, Anna Spreafico, Aaron R. Hansen, Simon S. McDade, Vicky M. Coyle, Mark Lawler, Elena Elimova, Scott V. Bratman, Lillian L. Siu
Summary: Immune checkpoint blockade is an important treatment for recurrent/metastatic head and neck squamous cell cancer, but only a subset of patients benefit from it. Monitoring plasma circulating tumor DNA (ctDNA) levels and changes during treatment can help assess disease burden and predict patient outcomes. This study showed that early changes in ctDNA after one cycle of treatment can predict progression-free survival and overall survival in patients with recurrent/metastatic head and neck squamous cell cancer.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Lisa Morkramer, Maren Geitner, Daniel Boeger, Jens Buentzel, Holger Kaftan, Andreas H. Mueller, Thomas Ernst, Orlando Guntinas-Lichius
Summary: The study presents valuable insights into patient characteristics, treatment patterns, and survival in a real-world population in Germany prior to the availability of immunotherapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Review
Medicine, General & Internal
Qiudong Xu, Shuang Huang, Kai Yang
Summary: This meta-analysis and systematic review assessed the efficacy and safety of combination immunochemotherapy for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The results showed that combination immunochemotherapy resulted in longer overall survival and progression-free survival, and higher objective response rate in R/M HNSCC patients. Although it did not increase the overall incidence of adverse effects, it significantly increased the rate of grade III and IV adverse effects.
Article
Oncology
Konrad Klinghammer, Luigi Lorini, Daan Nevens, Christian Simon, Jean-Pascal Machiels, Paolo Bossi
Summary: This study found that multiple factors differentially influence treatment decisions in the first line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), including performance status, PD-L1 expression, time from last systemic treatment, and disease burden. Prospective evaluation of patient characteristics and potential predictive biomarkers is important for stratifying personalized treatment for recurrent/metastatic HNSCC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Marco A. Mascarella, Tolani F. Olonisakin, Purva Rumde, Varun Vendra, Melonie A. Nance, Seungwon Kim, Mark W. Kubik, Shaum S. Sridharan, Robert L. Ferris, Moon J. Fenton, Daniel R. Clayburgh, James P. Ohr, Sonali C. Joyce, Malabika Sen, James G. Herman, Jennifer R. Grandis, Dan P. Zandberg, Umamaheswa Duvvuri
Summary: A study investigated the relationship between response to neoadjuvant therapy and survival in patients with head and neck squamous cell carcinoma. The analysis showed that patients who received targeted therapy had lower pathological stage migration and higher overall survival. The study also found a correlation between downstage migration and decreased levels of circulating tumor markers SOX17 and TAC1.
CLINICAL CANCER RESEARCH
(2023)
Review
Biochemistry & Molecular Biology
Soma Ghosh, Pooja A. Shah, Faye M. Johnson
Summary: Head and neck squamous cell carcinomas (HNSCCs) are common cancers that often recur and metastasize. Tobacco and alcohol use are associated with HNSCCs in the oral cavity and larynx, while HPV infection, particularly HPV16, is increasingly recognized as a cause of oropharyngeal HNSCC. Current treatment approaches have similar strategies for both HPV-positive and HPV-negative HNSCCs, but carry a high risk of toxic side effects. The landscape of HNSCC therapy is changing, with ongoing clinical trials investigating novel and less toxic treatment options.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Kiyoshi Minohara, Takuma Matoba, Daisuke Kawakita, Gaku Takano, Keisuke Oguri, Akihiro Murashima, Kazuhiro Nakai, Sho Iwaki, Wataru Hojo, Ayano Matsumura, Shinya Ozaki, Taijiro Ozawa, Ikuma Harata, Nobukazu Tanaka, Shinichiro Maseki, Hiroshi Tsuge, Sae Imaizumi, Shoji Mitsuya, Kazuho Moribe, Shinichi Esaki, Shinichi Iwasaki
Summary: This multicenter retrospective cohort study investigated the impact of clinico-hematological factors on survival in RM-HNC patients treated with nivolumab therapy. Patients without immune-related adverse events, lower relative eosinophil count, worse best overall response, higher performance status, and higher modified Glasgow Prognostic Score had worse survival outcomes. The novel prognostic score combining these factors was found to be associated with survival in RM-HNC patients.
SCIENTIFIC REPORTS
(2021)
Article
Primary Health Care
Claire Elizabeth Powers Smith, Vinayak Prasad
Summary: Targeted cancer therapies involve attacking specific genetic biomarkers found in certain cancers, and includes monoclonal antibodies, small molecule inhibitors, antibody-drug conjugates, and immunotherapy. While these therapies have improved survival for some incurable cancers, only a small percentage of patients qualify for targeted oncology medications and fewer actually benefit.
AMERICAN FAMILY PHYSICIAN
(2021)
Article
Oncology
Santiago Cabezas-Camarero, Maria Cruz Iglesias-Moreno, Elena Cerezo Druet, Miguel J. Sotelo, Salome Merino-Menendez, Maria Nieves Cabrera-Martin, Jose Carlos Plaza-Hernandez, Pedro Perez-Segura
Summary: Up to 10-15% of patients with platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) can be treated with the anti-PD1 nivolumab, which has shown positive response rates and overall survival. Patients with slow progressive disease and stable functional status can continue nivolumab beyond progression while monitoring toxicities. Local therapies like radiotherapy and surgical tumor resection can also be used to improve disease control and survival. This case contributes to the evidence for combining anti-PD1 agents and local therapies in selected patients with platinum-refractory HNSCC.
Article
Oncology
Shuchi Gulati, McKenzie Crist, Muhammed Kashif Riaz, Vinita Takiar, Maria Lehn, Ilaina Monroe, Sarah Palackdharry, Nicky Kurtzweil, Roman Jandarov, Nusrat Harun, Trisha M. Wise-Draper
Summary: The combination of cetuximab and durvalumab demonstrated durable activity with a tolerable safety profile in metastatic HNSCC and warrants further investigation.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Agnes Ducoulombier, Joel Guigay, Marie-Christine Etienne-Grimaldi, Esma Saada-Bouzid
Summary: This review discusses the clinical data on salvage chemotherapy used after checkpoint inhibitors, focusing particularly on recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Recent studies have shown high response and/or disease control rates associated with salvage chemotherapy after immunotherapy failure in various advanced solid tumors. These findings lay the groundwork for further prospective evaluation of postimmunotherapy salvage chemotherapy.
CURRENT OPINION IN ONCOLOGY
(2023)
Article
Geriatrics & Gerontology
C. Kenis, P. Heeren, L. Decoster, K. Van Puyvelde, G. Conings, F. Cornelis, P. Cornette, R. Moor, S. Luce, Y. Libert, R. Van Rijswijk, G. Jerusalem, M. Rasschaert, C. Langenaeken, A. Baitar, P. Specenier, K. Geboers, K. Vandenborre, P. R. Debruyne, K. Vanoverbeke, H. Van den Bulck, J. -P. Praet, C. Focan, V. Verschaeve, N. Nols, J. -C. Goeminne, B. Petit, J. -P. Lobelle, J. Flamaing, K. Milisen, H. Wildiers
JOURNAL OF NUTRITION HEALTH & AGING
(2016)
Review
Chemistry, Medicinal
J. Van den Bossche, F. Lardon, V. Deschoolmeester, I. De Pauw, J. B. Vermorken, P. Specenier, P. Pauwels, M. Peeters, A. Wouters
MEDICINAL RESEARCH REVIEWS
(2016)
Meeting Abstract
Oncology
K. Janssens, P. Specenier
EUROPEAN JOURNAL OF CANCER
(2017)
Article
Biotechnology & Applied Microbiology
Pol Specenier
EXPERT OPINION ON BIOLOGICAL THERAPY
(2017)
Article
Oncology
Leen Van den Steen, Olivier Vanderveken, Jan Vanderwegen, Dirk Van Gestel, Jean-Francois Daisne, Johan Allouche, Laurence Delacroix, Diane Van Rompaey, Sylvie Beauvois, Sophie Cvilic, Steven Marien, Gauthier Desuter, Jan Baptist Vermorken, Danielle Van den Weyngaert, Pol Specenier, Carl Van Laer, Marc Peeters, Paul Van de Heyning, Gilbert Chantrain, Georges Lawson, Cathy Lazarus, Marc De Bodt, Gwen Van Nuffelen
SUPPORTIVE CARE IN CANCER
(2017)
Editorial Material
Oncology
Nicole G. Chau, Roy B. Tishler, Robert I. Haddad
Article
Oncology
Pol Specenier
EXPERT REVIEW OF ANTICANCER THERAPY
(2018)
Review
Oncology
Pol Specenier, Jan B. Vermorken
EXPERT REVIEW OF ANTICANCER THERAPY
(2018)
Review
Oncology
Evelyne Roets, Karina Tukanova, Anouk Govarts, Pol Specenier
SUPPORTIVE CARE IN CANCER
(2018)
Editorial Material
Pharmacology & Pharmacy
Pol Specenier
EXPERT OPINION ON PHARMACOTHERAPY
(2019)
Article
Oncology
Jolien Van den Bossche, Christophe Deben, Ines De Pauw, HilDe lambrechts, Christophe Hermans, Vanessa Deschoolmeester, Julie Jacobs, Pol Specenier, Patrick Pauwels, Jan Baptist Vermorken, Marc Peeters, Filip Lardon, An Wouters
MOLECULAR ONCOLOGY
(2019)
Letter
Oncology
Evelyne Roets, Karina Tukanova, Anouk Govarts, Pol Specenier
SUPPORTIVE CARE IN CANCER
(2019)
Article
Oncology
Jolien Van den Bossche, Andreas Domen, Marc Peeters, Christophe Deben, Ines De Pauw, Julie Jacobs, Sven De Bruycker, Pol Specenier, Patrick Pauwels, Jan Baptist Vermorken, Filip Lardon, An Wouters
Article
Pharmacology & Pharmacy
Pol Specenier
EXPERT OPINION ON PHARMACOTHERAPY
(2020)
Article
Oncology
P. M. Specenier, E. Remenar, J. Buter, D. L. Schrijvers, C. Bergamini, L. F. Licitra, A. Awada, P. M. Clement, C. Fortpied, J. Menis, J. B. Vermorken
ANNALS OF ONCOLOGY
(2017)
